Moreover, some tumour antigen-specific CAR-T cells have finally entered clinical trials; five clinical trials investigated glypican-3, and other less conventional targets, including EpCAM, claudin 18.2, DR5, c-met, EGFRvIII and CD133, were also explored (NCT03013712, NCT03302403, NCT03638206, NCT03941626, NCT02541370). This evidence concerns the gene PROM1 and neoplasm.